Catalog No.
Product Name
Application
Product Information
Citations
-
GVIA iPLA2 Inhibitor
GK187 is a potent and selective inhibitor of Group VIA calcium-independent phospholipase A2 (GVIA iPLA2), exhibiting an XI(50) value of 0.0001. This compound demonstrates significant biological activity and potential for research in various neurological disorders, allowing for deeper insights into phospholipid metabolism and its implications in neurobiology. Its selectivity makes it a valuable tool for investigating the roles of GVIA iPLA2 in cellular processes and disease mechanisms. -
sPLA2 Inhibitor
AZD2716 is a selective inhibitor of secretory phospholipase A2 (sPLA2), specifically targeting sPLA2-IIa, sPLA2-V, and sPLA2-X with IC50 values of 10 nM, 40 nM, and 400 nM, respectively. By effectively reducing pro-inflammatory lipid production, AZD2716 diminishes macrophage activation and foam cell formation. This compound is valuable for investigating the pathways involved in atherosclerosis and various inflammatory diseases linked to sPLA2 activity. -
iPLA2γ Inhibitor
(R)-Bromoenol lactone is an irreversible chiral inhibitor targeting calcium-independent phospholipase γ (iPLA2γ). It exhibits potent inhibition of human recombinant iPLA2γ, with an IC50 value of approximately 0.6 µM. This compound is significant for research applications involving lipid signaling, inflammatory responses, and cellular metabolism. -
PLD Inhibitor
FIPI hydrochloride is a potent inhibitor of phospholipase D (PLD), exhibiting an IC50 of approximately 25 nM for both PLD1 and PLD2. This compound plays a critical role in regulating cytoskeletal reorganization, cell migration, and chemotactic responses, making it valuable for cancer research. Additionally, FIPI hydrochloride enhances the secretion and aggregation of platelet dense granules, contributes to thrombosis inhibition, reduces infarct volume in ischemic stroke models, and promotes recovery of neuronal function. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-2 is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), exhibiting an IC50 of 120 nM for recombinant human Lp-PLA2. This small molecule plays a significant role in modulating lipid metabolism and inflammatory processes associated with cardiovascular disease. It is valuable for research applications focused on understanding the biological implications of Lp-PLA2 in various pathophysiological conditions. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-5 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme implicated in the hydrolysis of lipoprotein and phospholipids. This compound demonstrates significant potential in research focused on various diseases related to Lp-PLA2 activity, including atherosclerosis and Alzheimer's disease. Its inhibition of Lp-PLA2 may provide insights into therapeutic strategies for managing lipid-related pathologies. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that plays a crucial role in the hydrolysis of lipoprotein lipids and phospholipids. This compound is valuable for investigating the biological effects of Lp-PLA2 in various pathological conditions, including atherosclerosis and Alzheimer's disease. Research applications include elucidating the enzyme's role in lipid metabolism and inflammation pathways. -
Phospholipase A2 Iinhibitor
Plipastatin A1 is a lipopeptide that serves as an inhibitor of phospholipase A2. It demonstrates significant inhibitory effects on the conidial germination of Botrytis cinerea, leading to a reduction in the occurrence of gray mold on tomato leaves. This compound is valuable for research focused on agricultural pathogens and plant protection strategies against gray mold disease. -
PLD Inhibitor
VU0155069 hydrochloride is a potent and selective inhibitor of phospholipase D (PLD), with IC50 values of 46 nM for PLD1 and 933 nM for PLD2. This compound effectively inhibits the migration of both human and mouse breast cancer cell lines, making it a valuable tool for studying the role of PLD in cancer biology. Its unique mechanism of action allows researchers to explore therapeutic strategies targeting PLD-related pathways in oncology. -
Lp-PLA2 Inhibitor
SB-435495 hydrochloride is a highly potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), characterized by its reversible and non-covalent action. With an IC50 value of 0.06 nM, it demonstrates significant inhibitory efficacy, making it a valuable tool for research into cardiovascular diseases and inflammatory conditions. This compound is suitable for studies focused on the role of Lp-PLA2 in atherosclerosis and other lipid metabolism-related disorders. -
Glycosphingolipid Sulfatide Derivative
Lyso-sulfatide (bovine) ammonium is a derivative of the glycosphingolipid sulfatide that functions as an extracellular signaling molecule. It is known to regulate the migration of neural precursor cells, specifically by rapidly inducing process retraction and cell rounding in B35 neuroblastoma cells. This compound is valuable for research applications in neurobiology and cellular signaling pathways. -
LYPLA1/LYPLA2 Inhibitor
ML378 is a dual inhibitor of LYPLA1 and LYPLA2, demonstrating IC50 values of 122 nM and 245 nM, respectively. In addition, ML378 exhibits potent inhibition of ABHD6 with an IC50 of 3.15 nM. This compound is valuable for investigating the physiological and pathological roles of LYPLA1 and LYPLA2 in various biological processes and disease models. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme involved in the hydrolysis of lipoprotein lipids. This compound demonstrates significant biological activity, making it a valuable tool for exploring the role of Lp-PLA2 in various pathological conditions, including atherosclerosis and Alzheimer’s disease. Lp-PLA2-IN-11 is suitable for research applications focused on the modulation of lipoprotein metabolism and the investigation of Lp-PLA2's contribution to disease progression. -
nSMase2 Inhibitor
DPTIP-prodrug 18 is an orally active prodrug that demonstrates high brain penetrability and functions as a potent nSMase2 inhibitor. It effectively inhibits IL-1β-induced release of extracellular vesicles by targeting and inhibiting the activity of neutral sphingomyelinase-2. This compound is suitable for research in brain injury studies, providing insights into the molecular mechanisms of neuroinflammation and extracellular signaling. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-9 is a tetracyclic pyrimidinone compound that functions as a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), exhibiting a pIC50 of 10.1 for recombinant human Lp-PLA2. This compound demonstrates significant biological activity that may be valuable in the study of neurodegenerative diseases and related pathologies, making it a useful tool for research aimed at understanding Lp-PLA2's role in neuroinflammation and its therapeutic potential. -
PLA2 Inhibitor
Ikshusterol 3-O-glucoside is a potent phospholipase A2 (PLA2) inhibitor derived from plant sources. This compound exhibits significant biological activity by effectively modulating inflammatory responses associated with PLA2 activity. Its applications in research include studying snake venom toxicity and exploring anti-inflammatory pathways, making it a valuable tool for investigations into immune response and venom pharmacology. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-17 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound is utilized in research to investigate the role of Lp-PLA2 in the hydrolysis of oxidized lipids, leading to the production of inflammatory mediators. Lp-PLA2-IN-17 is valuable in studying various inflammatory disorders and cardiovascular diseases linked to lipid metabolism. -
cPLA2 Inhibitor
AX048 is a selective inhibitor of calcium-dependent phospholipase A2 (cPLA2), exhibiting a potent inhibitory effect with an XI(50) of 0.022 mole fraction. This compound demonstrates significant antihyperalgesic efficacy, making it a valuable tool for research into pain mechanisms and inflammatory pathways. AX048 is applicable in studies focusing on neuropathic pain and the modulation of lipotoxicity-related conditions. -
cPLA2 Inhibitor
BMS-229724 is a potent, orally active inhibitor of cytosolic phospholipase A2 (cPLA2), exhibiting an IC50 of 2.8 μM. This compound effectively inhibits the production of arachidonic acid and eicosanoids in various cell types, including U937 cells, neutrophils, and platelets. With demonstrated anti-inflammatory properties, BMS-229724 is valuable for research into skin inflammation and related inflammatory diseases. -
cPLA2α Inhibitor
WAY-196025 is a selective, orally active inhibitor of cytosolic phospholipase A2 alpha (cPLA2α) with an IC50 of 0.01 μM and a Kd of 0.013 μM. This compound effectively inhibits the production of inflammatory mediators, including prostaglandins and leukotrienes, which are crucial in inflammatory responses. WAY-196025 is valuable for research applications in inflammation and immunology, particularly in studies related to asthma and other inflammatory diseases. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme involved in the hydrolysis of lipoprotein lipids and phospholipids. This compound exhibits significant biological activity in the context of neurodegenerative diseases, including Alzheimer's disease, as well as ophthalmic conditions such as glaucoma and age-related macular degeneration. Additionally, Lp-PLA2-IN-10 may have implications in cardiovascular research, particularly in relation to atherosclerosis. -
Itk
(±)-Armepavine hydrochloride is an Itk (interleukin-2-inducible T cell kinase) inhibitor that exhibits immunosuppressive effects on T lymphocytes. This compound has shown potential in mitigating autoimmune responses, as evidenced by its impact in lupus nephritic mouse models. Its distinct mechanism makes it a valuable tool for research in immunology and autoimmune disease studies. -
Lp-PLA2 Inhibitor
ML256 is a covalent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), a key enzyme involved in lipid metabolism and inflammation. This compound exhibits biological activity by selectively targeting Lp-PLA2, making it valuable in the investigation of neoplasms with constitutively active variants of KRAS or HRAS. It is useful for research applications focusing on cancer biology and the modulation of inflammatory pathways. -
Bee Venom Phospholipase A2 Inhibitor
AGN-190383 is a potent inhibitor of bee venom phospholipase A2, targeting key enzymes involved in inflammatory processes. It effectively inhibits both hormone-operated and depolarization-dependent calcium mobilization, as well as fMLP-stimulated increases in free cytosolic calcium levels. Due to its ability to modulate calcium signaling and exhibit anti-inflammatory activity, AGN-190383 is valuable for research applications in studying inflammation and calcium-related cellular responses. -
Phospholipase A2 Inhibitors
Ro 23-9358 is a selective inhibitor of secretory phospholipase A2, known for its potent anti-inflammatory properties. By targeting this enzyme, Ro 23-9358 modulates the release of pro-inflammatory lipid mediators, making it a valuable tool in studying inflammatory pathways. Its application is relevant in research focused on inflammatory diseases and the development of therapeutic strategies to mitigate inflammation. -
ASM Inhibitor
ASM-IN-2 is a potent inhibitor of acid sphingomyelinase (ASM), exhibiting an IC50 value of 0.87 μM. This compound plays a crucial role in reducing ceramide levels, which is linked to various antidepressant mechanisms of action. Notably, ASM-IN-2 demonstrates significant antidepressant effects in the chronic unpredictable mild stress (CUMS) mouse model, making it an important tool for research in the development of antidepressant therapies. -
RBBP9 Inhibitor
ML114 is a selective inhibitor of the serine hydrolase RBBP9, exhibiting an IC50 of 0.63 μM against recombinant RBBP9. This compound has been shown to suppress the proliferation of human pluripotent stem cells (hPSCs) by modulating the expression of NFYA and other associated factors, without triggering differentiation. ML114 is valuable for research in cancer pathology, particularly in the study of retinoblastoma. -
sPLA2-IIA Inhibitor
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK, specifically designed to target human Group IIA phospholipase A2 (hGIIA). This compound effectively binds to hGIIA, inhibiting its enzymatic activity and preventing the hydrolysis of glycerophospholipids. This inhibition leads to decreased production of free fatty acids, such as arachidonic acid, making it a valuable tool for studying inflammatory processes and lipid metabolism in various biological models. Its application is particularly relevant in research aimed at understanding related pathophysiological conditions. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-6 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with an exceptional pIC50 of 10.0 against recombinant human Lp-PLA2. This tetracyclic pyrimidinone compound is primarily utilized in research focusing on neurodegenerative diseases, where its biological activity may contribute to a deeper understanding of disease mechanisms and the development of therapeutic strategies. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-12 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound has shown potential in the study of neurodegenerative diseases such as Alzheimer's disease, as well as ocular conditions like glaucoma and age-related macular degeneration. Additionally, Lp-PLA2-IN-12 is relevant for research on cardiovascular diseases, including atherosclerosis, by modulating inflammatory processes associated with these conditions. -
Phospholipase A2 Inhibitor
Folipastatin is a potent inhibitor of phospholipase A2, demonstrating an IC50 value of 39 μM. This novel depsidone compound, derived from Aspergillus unguis, exhibits significant biological activity, making it a valuable tool for studies related to phospholipid metabolism and inflammatory processes. Its application extends to research on lipid signaling pathways and related cellular mechanisms. -
Phospholipid
1-Myristoyl-2-Linoleoyl-sn-glycero-3-PC is a phospholipid characterized by the presence of myristic acid at the sn-1 position and linoleic acid at the sn-2 position. This unique composition mirrors the lipid profile found in human plasma and is crucial for studying membrane dynamics and cell signaling pathways. It is commonly applied in research involving membrane biochemistry, lipid metabolism, and cellular function. -
SMS2 Inhibitor
SMS2-IN-3 is a potent and selective inhibitor of sphingomyelin synthase 2 (SMS2) with an IC50 of 2.2 nM. This compound significantly reduces hepatic sphingomyelin (22:0) levels, making it a valuable tool for research into sphingolipid metabolism and its implications in various metabolic disorders. SMS2-IN-3 is applicable in studies exploring the role of sphingolipids in health and disease. -
Sphingomyelinase Inhibitor
SM (d18:1/15:0) is an inhibitor of sphingomyelinase, a crucial enzyme involved in sphingolipid metabolism. This compound demonstrates potential in the study of neurodegenerative diseases such as Alzheimer's and metabolic syndrome. Its mechanism of action makes it a valuable tool for investigating the roles of sphingolipids in various cellular processes and disease states. -
HSF-PLA2 Inhibitor
Luffariellolide is a potent inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2), with an IC50 value of 5 μM. This compound has demonstrated significant anti-inflammatory activity, evidenced by its ability to effectively inhibit phorbol ester (PMA)-induced ear edema, with an ED50 of 50 μg/ear. Luffariellolide is a valuable tool for research applications focused on inflammation and lipid metabolism. -
PLA2 Inhibitor
MJ33-OH is a metabolite of MJ33, functioning as a specific, competitive, and reversible inhibitor of phospholipase A2 (PLA2). This compound effectively inhibits the activity of calcium-independent phospholipase A2 (iPLA2), particularly in the context of Prdx6 regulation. MJ33-OH is valuable for research applications focused on studying PLA2-related pathways and its implications in various biochemical processes. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-15 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound exhibits potent inhibitory activity, making it valuable for investigating the role of Lp-PLA2 in various biological processes. It is particularly relevant in Alzheimer's disease research and other studies related to inflammation and lipid metabolism. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-14 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with a pIC50 of 8.4 against recombinant human Lp-PLA2. This compound demonstrates significant potential in the study of neurodegenerative diseases, such as Alzheimer’s disease, glaucoma, and age-related macular degeneration, as well as cardiovascular conditions, including atherosclerosis. Lp-PLA2-IN-14 serves as a useful tool for researchers investigating the role of Lp-PLA2 in these pathologies. -
Sphingomyelinase Inhibitor
Brinazarone is a potent inhibitor of acid lysosomal sphingomyelinase, leading to the accumulation of sphingolipids within cells and resulting in cellular lipidosis. This compound enhances the cytotoxicity of specific immunotherapeutic agents, such as anti-Thy 1.2 AT15E RTA-IT on T2 cells and anti-CD5 T101 on CEM cells. Brinazarone is valuable for research applications involving sphingolipid metabolism and cancer immunotherapy studies. -
Lp-PLA2 Inhibitor
SB-435495 ditartrate is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), demonstrating a remarkable IC50 of 0.06 nM. This compound functions as a reversible, non-covalent inhibitor and is suitable for oral administration. Its inhibition of Lp-PLA2 has significant implications for research in cardiovascular diseases and inflammatory processes, making it a valuable tool for investigating pathophysiological roles and therapeutic interventions in related conditions. -
sPLA2 Inhibitor
Me-Indoxam is a potent inhibitor of secreted phospholipase A2 (sPLA2) that exhibits cell-impermeable characteristics. This compound effectively binds to the active site of sPLA2, disrupting its enzymatic function. Me-Indoxam is valuable in research applications focused on inflammation, cell signaling, and lipid metabolism, providing insights into the role of sPLA2 in various biological processes. -
PTDSS1 Inhibitor
DS07551382 is a selective inhibitor of phosphatidylserine synthase 1 (PTDSS1), effectively disrupting the intracellular synthesis of phosphatidylserine. This compound demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology. Its ability to modulate phosphatidylserine levels can provide insights into various signaling pathways involved in tumor progression and may aid in the development of novel therapeutic strategies. -
cPLA2α Inhibitor Derivative
cPLA2α-IN-derivative 1 is an inactive alcohol derivative designed to target cytosolic phospholipase A2α (cPLA2α). Although it exhibits no inhibition activity, it serves as a useful reference compound in structure-activity relationship studies. This reagent can be utilized in research focused on elucidating the role of cPLA2α in lipid metabolism and inflammatory responses. -
Phospholipase Inhibitor
A4333 is a biotinylated inhibitor of Phospholipase D1 (PLD1), selectively targeting this enzyme while sparing PLD2. This compound is significant in cancer research, demonstrating potent antitumor activity. Its specificity for PLD1 makes A4333 a valuable tool for elucidating the role of phospholipase signaling in tumor biology and potential therapeutic applications. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-16 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), a key enzyme implicated in inflammatory processes. This compound demonstrates potent inhibition of Lp-PLA2 activity, making it a valuable tool for investigating its role in neurodegenerative diseases, such as Alzheimer's disease. Its application in biochemical research supports studies focused on inflammation-related pathways and potential therapeutic targets. -
PLA2 Inhibitor
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA) functions primarily as a phospholipase A2 (PLA2) inhibitor, exhibiting selective inhibition against both P388D1 cell PLA2 (IC50 = 16 µM) and snake venom PLA2 (IC50 = 14 µM). As a non-metabolizable analog of arachidonic acid, DEDA serves as a valuable tool in biochemical studies related to PLA2 activity. Its unique properties make it suitable for researching inflammatory processes and signal transduction pathways modulated by phospholipid metabolism. -
Phospholipase A2 Inhibitor
Cinatrin A is a potent inhibitor of phospholipase A2, an enzyme involved in the hydrolysis of phospholipids, leading to the generation of inflammatory mediators. This compound exhibits significant anti-inflammatory properties and is valuable for research applications focused on inflammation, pain modulation, and related signaling pathways. Its mechanism of action makes it a valuable tool for studying phospholipid metabolism and the implications of phospholipase A2 in various diseases. -
Phospholipase Inhibitor
(R)-N-(1-Hydroxypropan-2-yl)palmitamide serves as a substrate analog inhibitor targeting phospholipase A2. This compound exhibits significant inhibition of enzymatic activity, making it valuable for research related to inflammatory processes and cellular signaling. Its application in studying phospholipid metabolism and lipid mediator synthesis further enhances its utility in biochemical and pharmacological investigations. -
cPLA2α Inhibitor
AVX001 is a selective inhibitor of cytosolic phospholipase A2 alpha (cPLA2α). This compound is instrumental in the study of inflammatory processes, particularly in conditions such as psoriasis. AVX001 modulates the release of arachidonic acid, thereby influencing eicosanoid signaling pathways, and provides valuable insights into therapeutic strategies targeting inflammatory disorders. -
nSMase Inhibitor
Chlorogentisylquinone is an inhibitor of neutral sphingomyelinase (nSMase), demonstrating an IC50 value of 1.2 μM against rat meningeal cells and 7.6 μM in P388 leukemia cells. This compound is derived from the strain FOM-8108 and serves as a valuable tool for studying the role of nSMase in cellular processes. Its biological activity makes it suitable for applications in neurobiology and cancer research.
